1. No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib monotherapy groups. 2. Serious adverse events ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Disease-free survival in the placebo group was 50.7 months and was never reached in the intervention group; however, there ...
1. Atezolizumab was associated with non-significantly increased disease-free survival compared to placebo (57.2 months vs. 49.5 months). 2. Serious adverse ...
1. Telaglenastat addition to cabozantinib did not show improvements in clinical benefit. 2. Adverse events of grades 3 or 4 ...
1. The median follow-up period for health-related quality-of-life (HRQOL) outcomes analyses was 12.9 months 2. For all FKSI-DRS, EORTC QLQ-C30 ...
